Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235753 | 0.86 | MAPK14 (0.35) | MAPK14CSNK1DCSNK1EMAPK10MAPK13 | |
| SCHEMBL3228998 | 0.84 | CSNK1D (0.40) | MAPK14CSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL3238739 | 0.75 | MAPK14 (0.36) | MAPK14CSNK1DCSNK1EMAPK10MAPK13 | |
| SCHEMBL2848948 | 0.67 | CSNK1D (0.39) | MAPK14CSNK1DCSNK1EMAPK10 | |
| SCHEMBL2842940 | 0.66 | MAPK14 (0.43) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL2842794 | 0.65 | MAPK14 (0.72) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL2845854 | 0.65 | MAPK14 (0.51) | MAPK14MAPK10 | |
| SCHEMBL3230372 | 0.63 | MAPK14 (0.39) | MAPK14CSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL2847860 | 0.62 | MAPK14 (0.73) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL1737010 | 0.58 | CYP1A2 (0.43) | MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-1853581-B1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-06-02 | — | — | EP | disclosed |
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | Merckle (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2054404-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1894925-A1 | Imidazole compounds having an antiinflammatory effect | MERCKLE GMBH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008023066-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| EP-1853581-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089798-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MIF, TNF, IL1B | MAPK14 2368/4885CSNK1D 2157/4885CSNK1E 1857/4885 |
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | MAPK14 1604/4885CSNK1D 1345/4885CSNK1E 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.